Recently, Ga-68-labeled short peptide ligand against prostate-specific membrane antigen (PSMA), developed originally for PET imaging of prostate cancer, was tested for PET imaging of HCC [30, 31]. This evidence concerns the gene FOLH1 and prostate carcinoma.